Purpose: The purpose of this 2-year follow-up study was to investigate the longterm effect of Remune as monotherapy for HIV-1 infection. Background: Participants previously enrolled in the phase II double-blind, randomized, adjuvantcontrolled study of the HIV-1 Immunogen (Remune) were followed for 2 years.Open-label immunization with Remune monotherapy was given to each participant every 12 weeks. Remune, a gp 120-depleted HIV-1 that was inactivated in betapropiolactone and irradiation, was emulsified with mineral oil (incomplete Freund’s adjuvant). Method: In Study 2101B, the effect of four doses of Remune given every 12 weeks over 40 weeks was compared to placebo in 297 asymptomatic type E HIV-infected patients [Churdboonchart et al., 2000]. A group of 17 volunteers were separated into a subset study and another 57 were excluded from analysis due to discontinuation or addition of other treatments. This 2-year follow-up study continued with open-label dosing of HIV-1 Immunogen every 12 weeks for the remaining 223 patients. Changes in CD4+ cells, CD8+ cells, and body weight were monitored at each patient visit. Results: Overall, immunizations were safe; common adverse events were tolerable injection site reactions. CD4+ T-cell counts remained stable over the 132-week observation period for this cohort with a slight increase of 36.01 cells/μL. CD8+ T-cell counts showed an increase from baseline during the follow-up period (415.21 cells/μL). Furthermore, we also observed an increase in body weight from baseline (1.08 kg) at week 132. In addition, baseline CD4 count appeared to predict CD4 count at week 132 (slope = 0.31, p < .0001). Conclusion: These results suggest that long-term treatment of HIV-1 infection with Remune monotherapy is safe and results in a stabilization of CD4+ counts. Furthermore, it is likely that HIV-1 therapeutic immunization may show its greatest clinical benefit in participants with higher CD4+ cell counts. Such an approach may have important ramifications in developing countries where access to antiviral drugs is limited and also in early chronic HIV-1 infection when CD4+ cells are still over 300 cells/μL in order to limit the cost and toxicity.

ปี 2544, September-October ปีที่: 2 ฉบับที่ 5 หน้า 391-398

Thailand, HIV-1 Immunogen, CD4, Remune